Author

Laurent Peyrin-Biroulet

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Laurent Peyrin-Biroulet  et al.

EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Laurent Peyrin-Biroulet  et al.

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION

Laurent Peyrin-Biroulet  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Laurent Peyrin-Biroulet  et al.

Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)
Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)

Laurent Peyrin-Biroulet  et al.

The real-world experience: Navigating the ocean of JAKi evidence to help improve outcomes for patients with UC (Pfizer Inc.) (Complete Session)
The real-world experience: Navigating the ocean of JAKi evidence to help improve outcomes for patients with UC (Pfizer Inc.) (Complete Session)

Laurent Peyrin-Biroulet  et al.

Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)
Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)

Laurent Peyrin-Biroulet  et al.

ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Laurent Peyrin-Biroulet  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Laurent Peyrin-Biroulet  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Laurent Peyrin-Biroulet  et al.

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Laurent Peyrin-Biroulet  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Laurent Peyrin-Biroulet  et al.

REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY
REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY

Laurent Peyrin-Biroulet  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Laurent Peyrin-Biroulet  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

Item 41 - 60 / 89
1 2
3
4 5